Treatment optimization in multiple sclerosis: how do we apply emerging evidence?
a MS Center Dresden, Center of Clinical Neuroscience , University Clinic Carl Gustav Carus, Dresden University of Technology , Dresden , Germany.
Tjalf
T
Ziemssen
a MS Center Dresden, Center of Clinical Neuroscience , University Clinic Carl Gustav Carus, Dresden University of Technology , Dresden , Germany.
Katja
K
Thomas
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D033183:Interdisciplinary Communication; D008279:Magnetic Resonance Imaging; D008991:Monitoring, Physiologic; D009103:Multiple Sclerosis / Q000628:therapy*; D020529:Multiple Sclerosis, Relapsing-Remitting; D058996:Quality Improvement; D011787:Quality of Health Care
D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D007166:Immunosuppressive Agents
Treatment optimization; high efficacy treatment; multiple sclerosis; no evidence of disease activity; treatment switch